Co-Authors
This is a "connection" page, showing publications co-authored by WILLIAM F SYMMANS and YUN GONG.
Connection Strength
0.746
-
Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol. 2007 Mar; 8(3):203-11.
Score: 0.291
-
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol. 2009 Sep 10; 27(26):4287-92.
Score: 0.086
-
Performance of chromogenic in situ hybridization on testing HER2 Status in breast carcinomas with chromosome 17 polysomy and equivocal (2+) herceptest results: a study of two institutions using the conventional and new ASCO/CAP scoring criteria. Am J Clin Pathol. 2009 Aug; 132(2):228-36.
Score: 0.086
-
Chromogenic in situ hybridization is a reliable method for detecting HER2 gene status in breast cancer: a multicenter study using conventional scoring criteria and the new ASCO/CAP recommendations. Am J Clin Pathol. 2009 Apr; 131(4):490-7.
Score: 0.084
-
Gene-expression microarrays provide new prognostic and predictive tests for breast cancer. Pharmacogenomics. 2007 Oct; 8(10):1359-68.
Score: 0.076
-
Optimal fixation conditions for immunocytochemical analysis of estrogen receptor in cytologic specimens of breast carcinoma. Cancer. 2004 Feb 25; 102(1):34-40.
Score: 0.059
-
A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
Score: 0.024
-
Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010 Nov 01; 16(21):5351-61.
Score: 0.023
-
Reproducibility of gene expression signature-based predictions in replicate experiments. Clin Cancer Res. 2006 Mar 15; 12(6):1721-7.
Score: 0.017